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The world’s microbiology laboratories can be a 
global microbial sensor network 
Thomas F. O’Brien, John Stelling 
     Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA 
The microbes that infect us spread in global and local epidemics, and the resistance genes that block 
their treatment spread within and between them. All we can know about where they are to track and 
contain them comes from the only places that can see them, the world’s microbiology laboratories, but 
most report each patient’s microbe only to that patient’s caregiver. 
Sensors, ranging from instruments to birdwatchers, are now being linked in electronic networks to 
monitor and interpret algorithmically in real-time ocean currents, atmospheric carbon, supply-chain 
inventory, bird migration, etc. To so link the world’s microbiology laboratories as exquisite sensors in a 
truly lifesaving real-time network their data must be accessed and fully subtyped. 
Microbiology laboratories put individual reports into inaccessible paper or mutually incompatible 
electronic reporting systems, but those from more than 2,200 laboratories in more than 108 countries 
worldwide are now accessed and translated into compatible WHONET files. These increasingly web-
based files could initiate a global microbial sensor network. 
Unused microbiology laboratory byproduct data, now from drug susceptibility and biochemical testing 
but increasingly from new technologies (genotyping, MALDI-TOF, etc.), can be reused to subtype 
microbes of each genus/species into sub-groupings that are discriminated and traced with greater 
sensitivity. Ongoing statistical delineation of subtypes from global sensor network data will improve 
detection of movement into any patient of a microbe or resistance gene from another patient, medical 
center or country. Growing data on clinical manifestations and global distributions of subtypes can 
automate comments for patient’s reports, select microbes to genotype and alert responders. 
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Los laboratorios de microbiología del mundo pueden convertirse en una red de detección microbiana
Los microbios que nos afectan se diseminan por epidemias locales y globales, y los genes resistentes 
que bloquean los tratamientos disponibles para combatirlos se reproducen dentro de ellos y se 
transmiten de unos a otros. Todo lo que sabemos sobre dónde rastrearlos y cómo contenerlos proviene 
de los únicos lugares en donde es posible examinarlos: los laboratorios de microbiología del mundo. 
Sin embargo, la mayoría de estos laboratorios reportan el microorganismo que afecta a cada paciente 
específico solamente a los responsables de la atención de ese paciente en particular. 
Los sensores, que van desde instrumentos hasta observadores de aves, se encuentran hoy conectados 
por redes electrónicas destinadas a monitorizar e interpretar por medio de algoritmos y en tiempo real 
las corrientes oceánicas, el carbono de la atmósfera, los inventarios de las cadenas de suministro, la 
migración de las aves, etc. La vinculación de los laboratorios de microbiología del mundo para que 
actúen como refinados detectores en una red dedicada a salvar vidas, requiere, no obstante, que sus 
hallazgos sean sometidos a subtipificación y que sus datos se puedan consultar sin restricción. 
Los reportes de los laboratorios de microbiología generalmente son documentos en papel que son 
inaccesibles o están en sistemas electrónicos de notificación mutuamente incompatibles. No obstante, 
actualmente los resultados de más de 2.200 laboratorios en más de 108 países han sido traducidos 
a los archivos compatibles de WHONET y están disponibles para consulta. Con estos archivos en la 
internet se podría iniciar una red global de detección microbiana. 
Los subproductos de información provenientes de los laboratorios de microbiología que hoy no se 
utilizan, como los datos sobre sensibilidad a medicamentos y los de pruebas bioquímicas, y aquellos 
que próximamente comenzarán a generar las nuevas tecnologías (genotipificación, técnicas de 
ionización suave [Matrix-Assisted Laser Desorption/Ionization Time-of-Flight, MALDI-TOF]), etc., 
pueden reutilizarse en la subtipificación de microorganismos de cada género y especie clasificados en 
subgrupos susceptibles de ser discriminados y rastreados con mayor precisión. 
La delineación estadística de los subtipos que actualmente se lleva a cabo con base en los datos de la 
red global de sensores mejorará la detección de la transmisión de cualquier microbio o gen resistente 
de un paciente a otro paciente, centro médico o país. La creciente cantidad de datos relativos a 
10
Biomédica 2014;34(Supl.1):9-15O’Brien TF, Stelling J
Microbiology laboratory data uniquely needs to 
be accessed and subtyped. 
When a caregiver sends a specimen from a patient 
to a laboratory it sends a report back to that 
caregiver. Reports from the microbiology laboratory 
differ from those of the other laboratories, such 
as hematology or biochemistry. The others report 
measurements of analytes, e.g., serum sodium or 
hemoglobin that are entirely contained within each 
patient. A microbiology laboratory reports that in or 
on that patient is a living microbe, which came from 
and may go to some place or someone else, and 
may also have information on where or who else. 
That microbiology laboratory or another may have 
information on whether any of the patients it tested 
had a microbe similar to one it is now reporting, and 
noticing who, when and where could reveal spread 
of a strain or incursion of a new one. Such noticing 
is limited by microbiology’s using only the one-
patient-to-one-caregiver reporting that is sufficient 
for the other laboratories lacking this need, but also 
because informatics for that noticing is only now 
becoming available (1). 
The world’s microbiology laboratories will have more 
information to track such spread when their data 
are all analyzed together, since microbial threats 
are increasingly seen as global epidemics (2-19). 
The strain of microbe infecting a patient anywhere 
now and the resistance gene blocking its treatment 
were rarely there a few years or decades earlier 
(20-26). Each had emerged somewhere, with its 
early global spread perhaps recorded unnoticed 
in some laboratory files, but then spread widely 
largely untracked and uncontained for lack of fully 
integrated real-time surveillance with alerting of 
responders (3, 27-30). Prompt recognition of the 
first incursion into a hospital or country of a new 
strain or resistance gene gives the best chance to 
contain its further spread (31). 
Microbiology data thus differ not only from data 
of the other laboratories but also from most other 
categories of patient data – blood pressure, body 
mass index, etc. Data of the other categories are so 
often interdependent that many kinds of healthcare 
analyses need to be across multiple such data 
categories. Microbiology reports an encounter 
of two independent living organisms, patient and 
microbe. The microbe has meaningful past lineage 
on other people and places, and more ahead (32). 
Microbiology data can thus often be accessed and 
analyzed in useful ways independently of other 
healthcare data (33).
The world’s microbiology laboratories can form 
a global microbial sensor network. 
Each report of the world’s microbiology laboratories 
goes mostly to one caregiver to guide care of one 
patient. Advances in informatics, however, now open 
the possibility of recycling these millions of already-
paid-for reports into an integrated network database 
to track spreading microbes and antimicrobial 
resistance genes everywhere, detect their outbreaks 
early and coordinate and focus their containment. 
Systems of this general kind are being developed 
and broadly termed electronic sensor networks. 
Sensors, ranging from weather-monitoring instru-
ments, through inventory-tracking workstations to 
birdwatchers are deployed widely and their sensed 
observations interconnected electronically, interpreted 
algorithmically and variously displayed (34,35). The 
e-bird network, for example, produces maps of the 
migration of any species of bird which locate its 
observed sightings day-by-day, displaying those on 
any day or advancing rapidly through a season. 
It would be helpful to have similar displays for 
a country, region or the whole world of the daily 
sightings (reports) of different kinds of emerging 
specific infecting microbes, with separate mapping 
of individual sightings of each antibiotype-defined 
or other subtype. It would be more useful to 
have, as do some sensor networks, continuous 
multi-parameter screening of data intake with 
automated alerting of pre-selected responders 
for various specific findings. Each of the world’s 
thousands of microbiology laboratories can be 
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las manifestaciones clínicas y la distribución global de subtipos puede incluir la automatización de 
comentarios en las historias clínicas, la selección de microorganismos para la subtipificación y la 
notificación de alertas a los responsables de salud.
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seen as a real-time sensor and an increasingly 
discriminating reporter of the microbes infecting 
patients in its area. 
Accessing the information of the world’s 
microbiology laboratories 
The first need for building a global microbial 
sensor network from the information of the 
world’s microbiology laboratories is to access that 
information from each laboratory. 
Their reports are now largely inaccessible either 
because they go only into paper reports and 
logbooks or into diverse electronic laboratory 
information systems (LISs) that are incompatible 
with one another. A resource for accessing the 
reports of a growing number of those laboratories 
from all parts of the world, however, has emerged 
from the global WHONET initiative. 
WHONET is a free software program developed 
and distributed by the World Health Organization 
Collaborating Centre for Surveillance of Antimicrobial 
Resistance, based at the Brigham and Women’s 
Hospital and Harvard Medical School, Boston, 
USA. Microbiology laboratories put their data 
into WHONET either by direct data entry or by an 
automatic translation from a laboratory information 
system facilitated by a data conversion utility 
(BackLink) which is included in WHONET (36,37). 
WHONET empowers each laboratory to analyze 
its data in multiple ways, e.g., percentage of 
all isolates of any kind or of any requested sub-
grouping that tested susceptible, intermediate or 
resistant to any or all tested antimicrobials for any 
time period, percentages and/or line-listings of all 
isolates that tested resistant to each combination 
of antimicrobials, scatter-plots of measurements 
of levels of susceptibility of isolates of any type to 
any pair of antimicrobials, etc. Additional functions, 
e.g. an outbreak-detection algorithm (SaTScan), 
continue to be added (38). 
As laboratories entered or translated their reports 
into WHONET their resulting WHONET files 
shared the same codes and structure and were 
thus inter-compatible and able to be merged to 
form both national and international multicenter 
surveillance networks (39). As a result, in a 
world where any two medical centers or medical 
center systems rarely have inter-compatible 
data they could share, there are now more 
than 2200 microbiology laboratories in more 
than108 countries around the world that have 
inter-compatible WHONET files. As WHONET 
now transitions to a web basis a growing subset 
of these files can be accessed to pilot a global 
microbial sensor network. 
Improving microbiology laboratory information 
by subtyping 
Microbiology laboratories have been paid for 
a century to report the genus/species identity 
of a microbe in a patient’s specimen –initially to 
anticipate the clinical syndromes but later also the 
probabilities of resistance to various antimicrobials 
associated with each identity. But species of 
microbes don’t spread and cause outbreaks. 
Strains of species spread, and so distinguishing 
strains from one another would optimize detection 
of spread. An outbreak of five cases in a month 
might be noticed if it were seen as the only isolates 
of a particular strain in that hospital that year, but 
not if seen only as five of several hundred isolates 
of that species that year. 
Subtyping isolates of one genus/species into 
smaller groupings will thus improve detection of 
outbreaks and tracking of spreading strains. Each 
of the subtypes of a larger grouping of microbes 
has had a more recent common ancestor and less 
time to diverge than the larger grouping. Ultimate 
subtyping to, or nearly to, the strain level would 
optimize detection and tracking, as shown by the 
many outbreaks tracked and contained by the long-
practiced serological subtyping of non-typhoidal 
salmonellae (40). But any subtyping that subdivided 
a genus/species into any number of sub-groups 
could enhance such detection and tracking in rough 
proportion to the number of such sub-groups. 
Most microbiology laboratories could subtype 
partially, and many extensively, with data they 
produce now, and most could soon subtype more. 
Most could subtype now by the antimicrobial 
susceptibility measurements they make for the 
up-to-half of their isolates that are insusceptible 
to at least one of the tested antimicrobials (41). 
Many could subtype further by the panels of up to 
48 biochemical tests they use now only to identify 
to the genus/species level. A laboratory may now 
labor to identify a rare species, but then issue a 
quarter of its reports only as Escherichia coli, which 
has many subgroups with differing epidemiology 
and clinical manifestations (42,43). 
Technology for further subtyping is growing. 
Microbiology laboratories are beginning to use 
matrix-assisted laser desorption ionization time-
of-flight (MALDI-TOF) instruments (44). They may 
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use them to identify only the genus/species of 
each microbe, as done now, and vendors may set 
them to do only that. MALDI-TOF can distinguish 
subtypes within each genus/species, however, 
but making that routine may require both wider 
recognition of the value of subtyping for strain-
tracking and outbreak detection, as sketched here, 
and informatics to manage it (45). 
Other subtyping technologies are coming into 
increasing use, such as multi-locus sequence 
typing (MLST), polymerase chain reaction (PCR), 
including that for 18s ribosomal RNA, and ultimately 
full genome nucleotide sequencing (46-49). These 
may be done selectively for problems of a patient 
or a hospital’s infection control, but informatics to 
capture, integrate and compare their results across 
hospitals will amplify their value. 
Reports from many academic centers throughout 
the world are being published that commonly 
have used multiple tests of these special kinds 
to describe in detail locally sampled epidemic or 
endemic microbes or their genetic elements. The 
publications may appear years after sampling and 
would be difficult to interrelate or overview. Many 
tests of these kinds, for example, are being done 
in many laboratories on strains carrying the KPC or 
NDM carbapenemases, but most of their results are 
now secluded in the files of scattered laboratories 
or publications. Integrating and analyzing together 
all those results in near-real time would greatly 
improve understanding of the spread of what are 
dreaded now as among the most menacing kinds 
of antimicrobial resistance (27,50). 
Example of the need for an integrated global 
subtyping process 
We have previously reported an example of the 
need for developing a globally integrated subtyping 
process (33). The minimal inhibitory concentrations 
(MICs) of two antibiotics for 5 blood and urine isolates 
of E. coli over a month from one patient distinguished 
them from any of the 3615 other isolates of E. coli 
tested by that laboratory that year. The patient had 
received a kidney transplant several months earlier 
at a hospital in a distant continent. The observation 
made in figure 2 of that report was noticed later by 
chance in a WHONET scatter-plot, which happened 
to be made for a different reason. 
The strain of E. coli isolated repeatedly from urine 
and blood of this returning foreign transplant 
recipient but from no other patient in the hospital 
that year was presumably acquired at the foreign 
transplant hospital, where it may have been 
widespread, and imported in the infected kidney. 
Many or most of the strains of resistant bacteria 
or of the resistance genetic elements circulating in 
any country, community, hospital or hospital ward 
may have first appeared in this way and in an index 
case such as this before spreading. Many may not 
have infected another cultured patient, as this one 
was not found to have done, but enough did to 
create the problems. 
This presumptive import happened to be noticed 
as a distinctive subtype by the very unlikely chance 
observation of only two of the measurements 
made routinely by the laboratory, which also 
routinely records on such isolates the results of 47 
biochemical tests and 4-6 MIC values for each of 
17 tested antimicrobials. Statistical comparisons 
of the results of all of these tests for this patient’s 
isolates with all of those for this hospital’s other E. 
coli isolates might have added further evidence for 
its being a distinctive subtype. 
The important lesson from this and other 
experiences is that optimal detection of such 
microbe movements needs integrated observation 
of so many variables on a global scale as to usually 
escape human noticing and require an informatics-
supported system with automated alerting.
Informatics for a global microbial sensor 
network tracking microbial subtypes 
The data management and processing needed to 
develop the optimal delineation of such subtypes 
and to automate the noticing and reporting of their 
problem interrelationships on a global level is 
now becoming available. Recent advances in 
informatic technology have made possible “Big 
Data” projects for management of massive 
databases, now often much larger than would 
be needed for a global microbial sensor network 
tracking microbial subtypes. 
An approach could be to begin with a sub-
typing system based initially only on qualitative 
antibiotypes, e.g., the combinations of antibiotics 
to which a microbe’s level of resistance exceeds 
the susceptible-intermediate breakpoint. These 
have generally been sufficiently stable on repeated 
isolates of the same genus/species from the same 
patient to infer sufficient identity of that strain in 
another patient to detect most such transfers 
(30,48,51,52). They have also been shown to 
greatly increase sensitivity of detection of clusters 
of cases in trials of the SaTScan program (53,54). 
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Artificial intelligence routines can be developed 
to help delineate the initial qualitative antibiotype-
based subtypes and to upgrade and reconfigure 
them and update their findings as global data 
grows. The same process could be extended to 
explore the advantages and problems of further 
subtyping by the use of quantitative antibiotypes, 
the combinations of antimicrobials that result from 
categorizing a microbe by the combinations of 
the measured levels of resistance to each of the 
antimicrobials to which it was tested. The resulting 
exponential expansion of the number of different 
antibiotypes would reduce their reproducibility but 
would enhance their sensitivity, as they did for the 
presumptive imported E. coli described above, 
which was detected by its quantitative antibiotype. 
The same process could be applied progressively 
to adding available data from results of other kinds 
of testing to further discriminate subtyping. An 
early example would be the results of the many 
biochemical tests generated routinely by microbe-
identifying instruments now in wide use, which we 
have shown to support biotyping. Increasingly 
used MALDI-TOF instruments appear to have, as 
mentioned above, potential for highly discriminating 
routine subtyping of all reported microbes if the 
value of subtyping is recognized and its vendors 
adjust it to report subtypes. 
Additional subtyping power will come from 
selectively but increasingly used genotyping 
tests. These include MLST, which pioneered 
the integrated global filing and interpretation of 
test results that we advocate here, PCR and the 
ultimate, full genome sequencing (46). These offer 
the highest discrimination of subtyping, but their 
selective use limits their availability. Integrating 
their results with the commonly available 
subtyping methods results, however, will amplify 
the value of both. Many of the isolates of the now-
threatening KPC and NDM-expressing strains of 
Enterobacteriaceae as mentioned above have, for 
example, been tested somewhere with one or more 
of these methods and retrieving and integrating all 
of that data could better delineate the subtyping 
and so also the epidemiology of that menace. 
A global electronic network interprets each 
patient’s microbe and also alerts responders. 
As a subtyping “engine” continues to distinguish 
and subdistinguish subtypes from the multiple 
kinds of data accumulating in its growing global 
database it can also record for each subtype its 
geographic distributions over time and its clinical 
characteristics, e.g., predominantly hospital or 
community-isolated, preferred anatomical sites 
of isolation, etc. It can also summarize these into 
commentary for each subtype and maintain an 
accessible updated dictionary of such comments. 
The electronic network would then locate the 
subtype of each patient’s microbe as a laboratory 
is about to report it and automatically present that 
subtype’s current comment for optional inclusion in 
the laboratory’s report to that patient’s caregiver. 
Another set of algorithmic analyses running on 
the growing global database would screen for 
unusual time-space distribution of any subtypes, 
as we have done successfully with SaTScan in 
hospitals and for certain kinds of microbes in 
regions of countries (53,54). Whenever a statistical 
threshold is exceeded for an area, an alert is sent 
automatically to responders pre-selected for that 
area. The areas for many such alerts would span 
multiple hospitals or even countries, and many 
of those responders would thus be in the only 
organizations with such broad jurisdiction, area 
public health agencies, which have often been less 
involved with antimicrobial resistance. 
This could fill what appears to be now a huge gap 
in the detection of spread particularly of subtypes 
of multidrug-resistant bacteria. Most hospitals have 
infection preventionists, each of whom works 
intensively to control such spread within their own 
hospital but often with little knowledge of what is 
in the next hospital, or in the chronic care facilities 
that send them patients or just beginning to come 
into that part of the country. Comprehensive, 
globally interpreted data shared between an area’s 
preventionists and its public health agencies with 
automated alerting of appropriate responders in 
both will help to close this gap.
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